AstraZeneca plc (ADR) (NYSE:AZN)

CAPS Rating: 4 out of 5

The Company discovers, develops, manufactures and markets prescription pharmaceuticals for important areas of healthcare: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.

Results 1 - 20 of 114 : 1 2 3 4 5 6 Next »

Recs

0
Member Avatar pest1948 (< 20) Submitted: 12/28/2014 3:52:20 PM : Outperform Start Price: $33.92 AZN Score: -0.30

appl

Recs

0
Member Avatar Herbstmd (50.05) Submitted: 8/12/2014 12:52:54 PM : Underperform Start Price: $32.87 AZN Score: +4.33

Government over regulation

Recs

0
Member Avatar charandy (49.47) Submitted: 8/12/2014 5:43:40 AM : Outperform Start Price: $32.77 AZN Score: -4.07

Depakote

Recs

0
Member Avatar JCG (< 20) Submitted: 5/26/2014 6:14:42 PM : Outperform Start Price: $33.66 AZN Score: -7.94

Astrazeneca makes lots of money

Recs

0
Member Avatar cajun1958 (< 20) Submitted: 5/25/2014 7:17:29 PM : Underperform Start Price: $33.66 AZN Score: +7.94

Whatever value PFE's merger attempt brought to light in AZN, it appears doubtful the company will be much more than a good yield instrument with a top end in the low 70s,

Recs

0
Member Avatar afewgoodstocks11 (< 20) Submitted: 2/21/2014 1:43:37 PM : Outperform Start Price: $18.67 AZN Score: +14.96

Div. (Yield) $2.70 (3.1%)
Current Yield . . . . . . 6.855%

Recs

0
Member Avatar Teacherman333 (92.84) Submitted: 7/25/2013 11:42:21 AM : Outperform Start Price: $23.15 AZN Score: +17.24

For reference point and to allow for comments by others. As of the end of March, 2013.

ROE 25.84%
Trailing PE 10.03
PB 2.83
Div yield 7.60%

Recs

0
Member Avatar IlluminatInvest (42.38) Submitted: 3/18/2013 5:02:08 PM : Outperform Start Price: $20.82 AZN Score: +26.41

Restructuring will cut fat while they restock their drug pipeline, and should eventually allow them to continue raising their dividend.

Recs

0
Member Avatar IlanBigfoot (78.46) Submitted: 12/30/2012 10:45:05 PM : Outperform Start Price: $20.12 AZN Score: +17.66

High yield strategy: TMFHighYield says to look for "high dividend payers from the S&P 500 from diverse sectors, relatively low debt, and a history of increasing dividend payments." This is my Health Care pick.
$46.88

Recs

1
Member Avatar gsauter157 (< 20) Submitted: 8/28/2012 9:05:49 AM : Outperform Start Price: $20.19 AZN Score: +18.65

New CEO

Recs

1
Member Avatar rainmaker59 (70.64) Submitted: 7/17/2012 3:19:51 PM : Outperform Start Price: $19.58 AZN Score: +18.73

Meets my metrics of low PE, high yield, eps, beta, roe and net profit. And 10 percent below 52-week high.

Recs

1
Member Avatar ihaveabaddober (32.74) Submitted: 5/23/2012 3:48:43 PM : Outperform Start Price: $17.31 AZN Score: +35.03

DIVIDEND/ROE MONSTER

Recs

0
Member Avatar outoffocus (23.76) Submitted: 4/27/2012 2:39:36 PM : Outperform Start Price: $18.45 AZN Score: +32.69

low p/e high div yield

Recs

0
Member Avatar Buffettinvestor (61.68) Submitted: 4/3/2012 3:01:59 PM : Outperform Start Price: $18.97 AZN Score: +28.43

Very cheap stock, with under 6 p/e, but still earning incredible returns on capital. Has been hit too hard among the pharmaceutical firms. Great contrarian play, with a great dividend Yield of over 6%.

Recs

0
Member Avatar recklessfier (< 20) Submitted: 3/8/2012 2:14:42 AM : Outperform Start Price: $18.97 AZN Score: +24.00

FDL1

Recs

0
Member Avatar campwt00global (33.20) Submitted: 1/4/2012 8:41:56 AM : Outperform Start Price: $19.22 AZN Score: +11.36

http://seekingalpha.com/article/317243-the-5-yield-solution

Recs

1
Member Avatar Chemdawg (25.63) Submitted: 10/8/2011 1:57:28 PM : Outperform Start Price: $19.00 AZN Score: +0.94

buybacks...great yield.... 10% off 52 week low

Recs

0
Member Avatar jmt587 (99.84) Submitted: 9/22/2011 2:10:02 PM : Outperform Start Price: $17.22 AZN Score: +10.01

Long Term Outperform.

Recs

0
Member Avatar d0w0kelley (< 20) Submitted: 8/28/2011 12:27:40 AM : Outperform Start Price: $18.81 AZN Score: +5.22

Large Cap stock trading above their 14-day SMA

Recs

0
Member Avatar STORMSTOCKER (< 20) Submitted: 8/11/2011 4:58:55 PM : Outperform Start Price: $18.14 AZN Score: +9.80

A MAJOR DRUG COMPANY THAT HAS BEEN BEATEN DOWN.

Results 1 - 20 of 114 : 1 2 3 4 5 6 Next »

Featured Broker Partners


Advertisement